Boston Family Office’s Enanta Pharmaceuticals ENTA Stock Holding History

Boston Family Office’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,850	Closed	-$203K	–	274
2022 Q1	$203K	Hold	2,850	–	–	0.01%	283
2021 Q4	$213K	Buy	+2,850	New	+$224K	0.01%	272
2019 Q3	–	Sell	-2,750	Closed	-$232K	–	256
2019 Q2	$232K	Hold	2,750	–	–	0.02%	243
2019 Q1	$263K	Buy	+2,750	New	+$247K	0.03%	230
2018 Q4	–	Sell	-2,750	Closed	-$235K	–	252
2018 Q3	$235K	Hold	2,750	–	–	0.02%	245
2018 Q2	$319K	Hold	2,750	–	–	0.04%	227
2018 Q1	$223K	Buy	+2,750	New	+$212K	0.03%	248

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Boston Family Office's ENTA Position: Q2 2022 in Review

Boston Family Office sold out of Enanta Pharmaceuticals (ENTA) in Q2 2022, closing a stake of 2,850 shares — an estimated $203K sold.

Boston Family Office first reported a position in ENTA in Q1 2018 and held it in 7 quarters. The position peaked at $319K in Q2 2018. 154 funds tracked by Wall St. Rank hold ENTA as of Q2 2022.

Boston Family Office reported no remaining Enanta Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Boston Family Office sold 2,850 Enanta Pharmaceuticals shares in Q2 2022, an estimated $203K.
Boston Family Office first reported a position in Enanta Pharmaceuticals in Q1 2018 and held it in 7 quarters.
Boston Family Office's Enanta Pharmaceuticals position peaked at $319K in Q2 2018.
154 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2022.

Based on Boston Family Office's 13F filing for Q2 2022, filed 11 Aug 2022.